Sign In
Buy NVO
$47.64
+0.230 (+0.485%)
At Close: Jun 25, 2026
Novo Nordisk's weight-loss drug Wegovy has been surpassed in weekly U.S. prescriptions by Eli Lilly's Zepbound, and now the company is trying to get back on track.
Novo Nordisk's Buy Scenario Is Supported By Quantitative Evidence
07:42am, Wednesday, 28'th May 2025
Novo Nordisk's sharp 54% decline is driven by LLY's competition, regulatory issues, and leadership change, but its fundamentals remain robust. Despite recent setbacks, NVO continues to deliver strong
Novo Nordisk's 52% Plunge: Is the Company Fumbling Its Leadership in the $150 Billion Weight Loss Market?
04:15am, Wednesday, 28'th May 2025
Nothing attracts competition like the opportunity for profits, and the weight loss drug market has become arguably the healthcare industry's hottest opportunity in recent memory. Novo Nordisk (NVO 4.5
Final Trade: ASML, XYZ, XLC, NVO
06:30pm, Tuesday, 27'th May 2025
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock Has More Upside?
01:41pm, Tuesday, 27'th May 2025
With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.
Novo Nordisk's GLP-1 lead narrows, but long-term thesis still holds
12:14pm, Tuesday, 27'th May 2025
A fresh physician poll has revived debate over the shifting balance of power in the weight-loss drug market. According to Deutsche Bank, the snapshot shows a marginal swing in favour of Eli Lilly and
Why Novo Nordisk Stock Just Popped
10:36am, Tuesday, 27'th May 2025
Over the weekend, President Trump offered to delay implementation of a new 50% tariff on imports from the European Union. The tariff, which was supposed to begin on June 1, now won't take effect until
Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock
10:06am, Monday, 26'th May 2025
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Is Novo Nordisk Immune To President Trump's Drug Price Plans
12:07am, Monday, 26'th May 2025
Despite Lars Fruergaard Jørgensen's resignation as Novo Nordisk's CEO, its stock price has risen 10% over the past two weeks. I believe this is due to the strong performance of its GLP-1 products and
Should everyone be taking drugs like Ozempic? Drugs in the GLP-1-category show promise for a growing list of health conditions
10:00pm, Sunday, 25'th May 2025
GLP-1 drugs for weight loss and treating diabetes show promise for an ever-expanding list of diseases.
Final Trade: AAPL, NVO, TLT, X
06:20pm, Friday, 23'rd May 2025
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Mizuho's Jared Holz talks what is next for Novo Nordisk
06:07pm, Friday, 23'rd May 2025
Mizuho's Jared Holz joins 'Fast Money' to talk what is next for Novo Nordisk as the stock struggles.
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies
12:15pm, Friday, 23'rd May 2025
NVO, CRBP and SKYE are tapping into the booming obesity market with novel CBD-based therapies, offering alternatives amid intensifying GLP-1 competition.
Novo Nordisk's High Risk/Reward Proposition: 129% Rally Or 65% Drop?
11:15am, Friday, 23'rd May 2025
Novo Nordisk A/S (NOVO-B) has entered the 18th and final phase of its long-term Weekly Adhishthana Cycle, marking a potentially transformative period. While the weekly charts point to a possible Nirva
3 Overlooked Dividend Growers With 10%+ Annual Dividend Increases
10:10am, Thursday, 22'nd May 2025
These dividend stocks can significantly amplify the compounding of your portfolio.
